$922 Million is the total value of VR Adviser, LLC's 28 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 44.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TIL | New | INSTIL BIO INC | $172,176,000 | – | 6,865,076 | +100.0% | 18.68% | – |
| CNST | CONSTELLATION PHARMACEUTICAL | $93,955,000 | -18.8% | 4,016,873 | 0.0% | 10.19% | -40.1% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $93,759,000 | +641.3% | 3,720,582 | +90.3% | 10.17% | +446.9% |
| OLMA | OLEMA PHARMACEUTICALS INC | $50,971,000 | -31.0% | 1,536,193 | 0.0% | 5.53% | -49.1% | |
| ALT | Sell | ALTIMMUNE INC | $49,455,000 | -2.6% | 3,500,000 | -22.2% | 5.36% | -28.1% |
| CGEM | New | CULLINAN MANAGEMENT INC | $49,010,000 | – | 1,176,145 | +100.0% | 5.32% | – |
| KNTE | KINNATE BIOPHARMA INC | $45,899,000 | -21.7% | 1,473,014 | 0.0% | 4.98% | -42.2% | |
| TRILLIUM THERAPEUTICS INC | $43,390,000 | -27.0% | 4,040,000 | 0.0% | 4.71% | -46.1% | ||
| Buy | MARINUS PHARMACEUTICALS INC | $40,895,000 | +29.5% | 2,641,809 | +2.0% | 4.44% | -4.5% | |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $34,725,000 | +91.2% | 16,302,596 | +74.2% | 3.77% | +41.1% |
| ATHA | ATHIRA PHARMA INC | $31,126,000 | -46.3% | 1,691,623 | 0.0% | 3.38% | -60.4% | |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $30,041,000 | +40.1% | 853,206 | +27.6% | 3.26% | +3.4% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC | $25,557,000 | +82.3% | 1,240,610 | +55.1% | 2.77% | +34.5% |
| PHVS | New | PHARVARIS BV | $25,335,000 | – | 902,882 | +100.0% | 2.75% | – |
| KROS | Sell | KEROS THERAPEUTICS INC | $22,915,000 | -51.7% | 372,306 | -44.6% | 2.49% | -64.3% |
| EPIX | New | ESSA PHARMA INC | $18,178,000 | – | 625,754 | +100.0% | 1.97% | – |
| KURA | KURA ONCOLOGY INC | $16,255,000 | -13.4% | 575,000 | 0.0% | 1.76% | -36.1% | |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $13,232,000 | -46.7% | 591,782 | -46.9% | 1.44% | -60.6% |
| ACET | New | ADICET BIO INC | $13,080,000 | – | 1,000,000 | +100.0% | 1.42% | – |
| New | APTOSE BIOSCIENCES INC | $9,592,000 | – | 1,605,400 | +100.0% | 1.04% | – | |
| COGT | COGENT BIOSCIENCES INC | $9,560,000 | -21.8% | 1,088,817 | 0.0% | 1.04% | -42.3% | |
| ALGS | Buy | ALIGOS THERAPEUTICS INC | $9,286,000 | -17.1% | 408,377 | +0.9% | 1.01% | -38.8% |
| EYPT | New | EYEPOINT PHARMACEUTICALS INC | $7,112,000 | – | 700,000 | +100.0% | 0.77% | – |
| BCTG | BCTG ACQUISITION CORP | $5,560,000 | -2.8% | 500,000 | 0.0% | 0.60% | -28.3% | |
| MTCR | Sell | METACRINE INC | $4,216,000 | -22.7% | 680,000 | -2.0% | 0.46% | -43.0% |
| SBTX | Sell | SILVERBACK THERAPEUTICS INC | $3,709,000 | -46.6% | 85,000 | -43.3% | 0.40% | -60.7% |
| TSHA | Buy | TAYSHA GENE THERAPIES INC | $2,449,000 | -14.5% | 120,649 | +11.7% | 0.27% | -36.8% |
| VRDN | VIRIDIAN THERAPEUTICS INC | $326,000 | +1.6% | 19,495 | 0.0% | 0.04% | -25.5% | |
| BCAB | Exit | BIOATLA INC | $0 | – | -100,000 | -100.0% | -0.50% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -245,122 | -100.0% | -0.61% | – |
| GRTX | Exit | GALERA THERAPEUTICS INC | $0 | – | -917,860 | -100.0% | -1.38% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -1,442,895 | -100.0% | -1.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.